Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
Compass Therapeutics (CMPX) Stock Price & Analysis
170 Followers
CMPX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.15 - $3.62
Previous Close$1.47
Volume106.51K
Average Volume (3M)377.46K
Market Cap
$202.26M
Enterprise Value$51.53M
Total Cash (Recent Filing)$152.46M
Total Debt (Recent Filing)$1.73M
Price to Earnings (P/E)-4.4
Beta0.92
Next Earnings
May 06, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding137,589,171
10 Day Avg. Volume514,349
30 Day Avg. Volume377,456
Standard Deviation0.27
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$9.67Price Target Upside548.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Compass Therapeutics News
PremiumCompany Announcements
Compass Therapeutics’ CTX-009 Gains FDA Fast Track Status
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe combination therapy of CTX-009 and CTX-471 demonstrates significant potential in eliminating MHC-1 negative tumors, offering a new hope for patients with these resistant cancers.
Financial HealthWith a solid cash position, the company is well-financed to support ongoing operations and clinical trials into mid-2026, ensuring continued progress in its innovative pipeline.
Regulatory MilestonesFDA clearance for CTX-8371 marks a major regulatory milestone, paving the way for further clinical development and potentially enhancing treatment options for patients.
Bears Say
Clinical Trial EfficacyAn objective response rate (ORR) below 10% will likely not meet the internal efficacy threshold for pursuing a monotherapy opportunity, indicating a possible setback if results do not meet expectations.
Drug Development DelaysThe importance of Compass Therapeutics' CTX-009 monotherapy in colorectal cancer has diminished due to trial enrollment delays and a shift in the investment thesis.
Safety ConcernsAs a reminder, many of the CD137 programs have had hepatoxicity, especially when CPI is part of the intervention.
---
Ownership Overview
35.66% Insiders
5.93% Mutual Funds
5.55% Other Institutional Investors
52.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.15 and its highest was $3.62 in the past 12 months.
What is Compass Therapeutics’s market cap?
Currently, no data Available
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 11 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Mar 21, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.016.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -$0.11.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 137,589,170 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went up 5.66%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Among the largest hedge funds holding Compass Therapeutics’s share is Blackstone Inc.. It holds Compass Therapeutics’s shares valued at 10M.
---
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (548.99% Upside)
$9.67 (548.99% Upside)
Hedge Fund Trend
Increased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.64%
12-Months-Change
Fundamentals
Return on Equity
-25.74%
Trailing 12-Months
Asset Growth
-21.42%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
---
CMPX Stock 12 Months Forecast
Average Price Target
$9.67
▲(548.99% Upside)
Technical Analysis
Best Analysts Covering CMPX
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
+8.33%
reiterated a buy rating last month
Copying Andrew Berens's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +8.33% per trade.
---